Peritoneal neoplasm
diseaseOn this page
Also known as neoplasm of peritoneumperitoneum neoplasmperitoneum neoplasm (disease)peritoneum tumorperitoneum tumourtumor of peritoneumtumour of peritoneum
Summary
Peritoneal neoplasm (MONDO:0006901) is a cancer and 76 clinical trials. Top therapeutic interventions include bevacizumab, doxorubicin, and gemcitabine. A subtype of neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 76
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | peritoneal neoplasm |
| Mondo ID | MONDO:0006901 |
| EFO | EFO:1001100 |
| MeSH | D010534 |
| NCIT | C3322 |
| SNOMED CT | 126865007 |
| UMLS | C0031149 |
| MedGen | 18392 |
| MedDRA | 10061344 |
| Anatomy (UBERON) | UBERON:0002358 |
| Is cancer (heuristic) | yes |
Also known as: neoplasm of peritoneum · peritoneal neoplasm · peritoneum neoplasm · peritoneum neoplasm (disease) · peritoneum tumor · peritoneum tumour · tumor of peritoneum · tumour of peritoneum
Disease family
This is a subtype of neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › peritoneal neoplasm
Related subtypes (47): pre-malignant neoplasm, endocrine gland neoplasm, giant cell tumor, hematopoietic and lymphoid system neoplasm, skin neoplasm, mesenchymal cell neoplasm, epidural spinal canal neoplasm, skeletal muscle neoplasm, trophoblastic neoplasm, cancer, germ cell tumor, benign neoplasm, upper aerodigestive tract neoplasm, histiocytoma, embryonal neoplasm, head and neck neoplasm, epithelial neoplasm, reproductive system neoplasm, non-seminomatous lesion, odontogenic cyst, phosphaturic mesenchymal tumor, thyroglossal duct cyst, hamartoma, mesenchymoma, mesothelial neoplasm, virus associated tumor, nail tumor, respiratory tract neoplasm, spindle cell neoplasm, mixed neoplasm, urinary system neoplasm, cystic neoplasm, childhood neoplasm, melanocytic neoplasm, digestive system neoplasm, nervous system neoplasm, neoplasm of thorax, connective tissue neoplasm, bronchial adenomas/carcinoids childhood, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, erythroplakia, retroperitoneal neoplasm, cardiovascular neoplasm, dermoid or epidermoid cyst of the central nervous system, connective and soft tissue neoplasm, NTRK fusion positive cancer, RET fusion positive cancer
Subtypes (4): peritoneal benign neoplasm, peritoneum cancer, peritoneal mesothelioma, peritoneal solitary fibrous tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 16 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Bevacizumab | Approved (phase 4) |
| Mirvetuximab Soravtansine | Approved (phase 4) |
| Alvimopan | Phase 3 (in late-stage trials) |
| Atezolizumab | Phase 3 (in late-stage trials) |
| Binimetinib | Phase 3 (in late-stage trials) |
| Bupivacaine | Phase 3 (in late-stage trials) |
| Carboplatin | Phase 3 (in late-stage trials) |
| Cisplatin | Phase 3 (in late-stage trials) |
| Doxorubicin | Phase 3 (in late-stage trials) |
| Epoetin Alfa | Phase 3 (in late-stage trials) |
| Gemcitabine | Phase 3 (in late-stage trials) |
| Isophenoxodiol | Phase 3 (in late-stage trials) |
| Paclitaxel | Phase 3 (in late-stage trials) |
| Patupilone | Phase 3 (in late-stage trials) |
| Rucaparib | Phase 3 (in late-stage trials) |
| Tamoxifen | Phase 3 (in late-stage trials) |
| Thalidomide | Phase 3 (in late-stage trials) |
| Trebananib | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aldesleukin, Alisertib, Allopurinol, Amifostine, Belinostat, Bicalutamide, Capecitabine, Carboxyamidotriazole, Catumaxomab, Celecoxib, Cetuximab, Decitabine, Denileukin Diftitox, Enzastaurin, Epoetin Beta, Farletuzumab, Filgrastim, Floxuridine, Fludarabine Phosphate, Fluorouracil, Ganciclovir, Gefitinib, INTERFERON GAMMA-1B, Ifosfamide, Irinotecan, Irofulven, Ixabepilone, Lapatinib, Letrozole, Mifepristone, Nintedanib, Nivolumab, Olaparib, Oregovomab, Oxaliplatin, Pazopanib, Pegfilgrastim, Pembrolizumab, Pemetrexed, Pertuzumab, Rubitecan, Sargramostim, Sunitinib, Tetanus Toxoid, Tirapazamine, Tisotumab Vedotin, Topotecan, Trabectedin, Vandetanib, Volociximab.
Clinical trials & evidence
Clinical trials
Clinical trials: 76.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 23 |
| Not specified | 17 |
| PHASE3 | 15 |
| PHASE1 | 14 |
| PHASE1/PHASE2 | 4 |
| PHASE2/PHASE3 | 2 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01932125 | PHASE4 | COMPLETED | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer |
| NCT02758951 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases |
| NCT04111978 | PHASE3 | RECRUITING | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) |
| NCT04498117 | PHASE3 | ACTIVE_NOT_RECRUITING | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery |
| NCT05257408 | PHASE3 | ACTIVE_NOT_RECRUITING | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
| NCT07213804 | PHASE3 | RECRUITING | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer |
| NCT00191607 | PHASE3 | COMPLETED | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. |
| NCT00191646 | PHASE3 | COMPLETED | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy |
| NCT00216372 | PHASE3 | COMPLETED | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis |
| NCT00262990 | PHASE3 | COMPLETED | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer |
| NCT00382811 | PHASE3 | COMPLETED | OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
| NCT00443196 | PHASE2/PHASE3 | COMPLETED | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas |
| NCT01015118 | PHASE3 | COMPLETED | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer |
| NCT01462890 | PHASE3 | COMPLETED | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer |
| NCT01846611 | PHASE3 | COMPLETED | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT02231086 | PHASE3 | COMPLETED | Adjuvant HIPEC in High Risk Colon Cancer |
| NCT03038100 | PHASE3 | COMPLETED | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT03740165 | PHASE3 | COMPLETED | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) |
| NCT02571725 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer |
| NCT06906341 | PHASE2 | RECRUITING | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers |
| NCT07273396 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer |
| NCT00004547 | PHASE2 | COMPLETED | Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy |
| NCT00035100 | PHASE2 | COMPLETED | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer |
| NCT00063401 | PHASE2 | COMPLETED | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
| NCT00074867 | PHASE2 | COMPLETED | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer |
| NCT00103545 | PHASE1/PHASE2 | COMPLETED | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response |
| NCT00112086 | PHASE2 | COMPLETED | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 |
| NCT00180960 | PHASE2 | TERMINATED | Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia |
| NCT00183794 | PHASE2 | COMPLETED | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma |
| NCT00189345 | PHASE2 | COMPLETED | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients |
| NCT00317772 | PHASE1/PHASE2 | COMPLETED | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer |
| NCT00318370 | PHASE2 | COMPLETED | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy |
| NCT00332696 | PHASE2 | COMPLETED | Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis |
| NCT00352755 | PHASE2 | TERMINATED | A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis |
| NCT00391118 | PHASE2 | COMPLETED | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (Sugar Pill) |
| NCT00445549 | PHASE2 | TERMINATED | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00516841 | PHASE2 | TERMINATED | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer |
| NCT00517621 | PHASE2 | COMPLETED | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire |
| NCT00698451 | PHASE2 | COMPLETED | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers |
| NCT01681368 | PHASE2 | TERMINATED | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 6 |
| DOXORUBICIN | 4 | 4 |
| GEMCITABINE | 4 | 2 |
| OLAPARIB | 4 | 2 |
| TOPOTECAN | 4 | 2 |
| AMINOCAPROIC ACID | 4 | 1 |
| ATEZOLIZUMAB | 4 | 1 |
| NINTEDANIB | 4 | 1 |
| PEMBROLIZUMAB | 4 | 1 |
| TRABECTEDIN | 4 | 1 |
| TREMELIMUMAB | 4 | 1 |
| VANDETANIB | 4 | 1 |
| PATUPILONE | 3 | 2 |
| ENZASTAURIN | 3 | 1 |
| FARLETUZUMAB | 3 | 1 |
| ISOPHENOXODIOL | 3 | 1 |
| OREGOVOMAB | 3 | 1 |
| SEMAXANIB | 3 | 1 |
| VOLOCIXIMAB | 3 | 1 |
| BIRINAPANT | 2 | 1 |
| FELMETATUG VEDOTIN | 2 | 1 |
| IDRONOXIL | 2 | 1 |
| OSI-632 | 2 | 1 |
| KHK-2866 | 1 | 1 |
| CHEMBL5412235 | 0 | 1 |
| CHEMBL5175478 | 0 | 1 |
| CHEMBL454299 | 0 | 1 |
| S-ROLIPRAM | 0 | 1 |